In 2025, health means staying alive from the inside. Taking advantage of the bedeviled blessing of insurance, scheduling ...

Factors associated with multi-b/tsDMARD failure among patients with PsA included female sex, obesity, depression, axial disease, and increased disease activity.

Fresenius Kabi, an operating company of Fresenius, announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent, product-specific billing code for Otulfi® ...

The EC has granted marketing authorisation for Johnson & Johnson's (J&J) Tremfya to treat adults with ulcerative colitis (UC) ...

Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in ...

Learn more about whether Alvotech or Kymera Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, ...

Otulfi is FDA-approved for subcutaneous and intravenous formulations to treat the same conditions as Stelara (ustekinumab), including Crohn’s disease, ulcerative colitis, moderate to severe plaque ...

Johnson & Johnson has filed its IL-23 inhibitor Tremfya for approval in psoriatic arthritis (PsA), its second ... has been approved in the US for moderate-to-severe plaque psoriasis since 2017.

Retronychia occurs when toenails grow backward into surrounding tissue. Learn the 7 symptoms, common causes, and treatment options for this painful condition.

Atopic dermatitis (AD) is a very common, heterogeneous and debilitating disease with a need for new treatment optionsCAN10 targets several pathways relevant for AD but distinct from current treatments ...

AbbVie today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA).1 This comes ...